Research Article (Open access) |
---|
ABSTRACT- Background: Viral hepatitis B and C can lead to the end stage liver disease and diabetes mellitus is also a life-long chronic disease. Simultaneous presences of both of these conditions lead to synergistic detrimental outcome. So identification of diabetes mellitus at the initial evaluation of a patient having chronic hepatitis B and C is essential.
Materials and methods: This study was designed as a retrospective single center cross-sectional study. The association of viral hepatitis B and C with diabetes mellitus was investigated at the Liver Centre Dhaka, Bangladesh for a period of 12 years. HBsAg was tested for hepatitis B virus infection and anti-HCV for hepatitis C virus infection. Demographic profile and biochemical data were retrieved from records.
Results: A total of 29425 cases were analyzed in the study [median age 31(19–95) years, 24615(84%) males]. HBsAg positive were 27475 and hepatitis C were 1950. Patients with hepatitis C were older than hepatitis B (p<0.001). Although previous history of jaundice was similar in both infections but history of blood transfusion was more common among hepatitis C patients (p<0.001). Analyzing different conditions of liver disease, it was observed that hepatitis B virus infection was highly responsible for acute hepatitis than hepatitis C (10.7% vs 1.1%) (p<0.001). Chronic hepatitis was similar in rate (73.3% vs 59.9%). But in both conditions of cirrhosis of liver like compensated and decompensated states, hepatitis C virus was significantly responsible than the hepatitis B virus 24.7% vs 9.6% (p<0.001) and 14.3% vs 6.4% (p<0.001) respectively. The most significant finding was very higher rate of diabetes among hepatitis C which was 22.6% while only 1.8% among hepatitis B virus infection (p<0.001).
Conclusion: Hepatitis C virus was highly related with the presence of diabetes than hepatitis B.
Key-words- Diabetes mellitus, Prevalence, Hepatitis B virus, Hepatitis C virus
INTRODUCTION
Globally two billion people are infected with HBV, and 350 millions of them have chronic (lifelong) infections, who are at high risk of death from liver cirrhosis and liver cancer that kill more than one million people globally each year.[1] Different studies in Bangladesh showed that seroprevalence of hepatitis B is 3.1-4-2%.[2-4] A recent report showed 5.5% HBsAg positivity among the general population living in Savar, a semi-urban area on the outskirts of Dhaka.[5]
HCV infections is also a major global health problem with an estimated 170 million people chronically infected and 3-4 million people get new infections each year.[6] A recent study among rural population in Bangladesh showed only 0.5% subjects were positive for anti-HCV antibodies.[7] In a recently published article sero prevalence of hepatitis B and hepatitis C were 3.0% and 0.48% respectively among diabetics.[8] These findings are similar to previous studies.
disability worldwide.[9-10] Its global prevalence was about 8% in 2011 and is predicted to rise 10% by 2030. [11] Nearly 80% of people with diabetes live in low and middle-income countries.[11] Asia and the Eastern Pacific region are particularly affected: in 2011, China was home to the largest number of adults with diabetes (i.e. 90.0 million, or 9% of the population), followed by India (61.3 million, or 8% of the population) and Bangladesh (8.4
million, or 10% of the population).[11] In Bangladesh, the overall age-adjusted prevalence of diabetes and prediabetes is 9.7% and 22.4%, respectively.12 Among urban residents, the age-adjusted prevalence of diabetes is 15.2% compared with 8.3% among rural residents. [12]
Frequency of diabetes among hepatitis B and hepatitis C viruses are studied in some places. In a study among Japanese populations, it was shown that he prevalence of DM was higher in HCV-infected patients (20.9%; P<0.02) than in HBV-infected subjects (11.9%). [13] In the cirrhotic patients, DM was observed in 30.8% of the subjects with HCV compared with 11.8% of those with HBV ( P< 0.01).[13]
Treating chronic hepatitis with available injectable and oral agents needs patients’ assessment for the presence of co-morbid diseases like diabetes. This study was aimed to look for the presence of diabetes among hepatitis B and hepatitis C patients at the time of initial diagnosis.
MATERIALS AND METHODS
Study design and patients: This was a retrospective single center cohort study that included the data of patients with chronic HBV and HCV infection from The Liver Centre, Dhaka, Bangladesh between January 2001 to December 2012. Patients older than 18 years, who had been diagnosed with chronic HBV and HCV infections were included in the study. Results of blood tests like serum ALT, fasting blood glucose, 2 hours post prandial glucose, HbA1C, HBsAg and anti-HCV were retrieved from records.
Statistical analyses: The Statistical Package for the Social Sciences (SPSS)-23 (SPSS Inc.; Chicago, IL, USA) package program was used for statistical analyses. Categorical variables were presented as the number of cases and percentages, continuous variables with a normal distribution were presented as mean±standard deviation, and continuous variables without a normal distribution were presented as median (minimum-maximum). Categorical variables were compared using a chi-squared test. A p-value of <0.05 was considered statistically significant. Ethics committee approval was obtained from the ethics committee of Hepatology Society, Dhaka, Bangladesh.
RESULTS
This study comprised of 29425 cases [median age 31 (19–95) years, 24615(84%) males]. HBsAg positive cases were 27475 and hepatitis C was 1950. Patients with hepatitis C were older than hepatitis B (p<0.001) (Table 1). Previous history of jaundice was similar in both infections but history of blood transfusion was more common among hepatitis C virus patients (p<0.001). Analyzing different conditions of liver disease and viral a etiology, it was observed that hepatitis B virus infection was highly responsible for acute hepatitis than hepatitis C (10.7% vs 1.1%) (p<0.001). Chronic hepatitis was similar in rate (73.3% vs 59.9%). But in both conditions of cirrhosis of liver like compensated and de-compensated states, hepatitis C virus was significantly responsible than the hepatitis B virus 24.7% vs 9.6% (p<0.001) and 14.3% vs 6.4% (p<0.001) respectively. The most significant finding was very higher rate of diabetes among hepatitis C which was 22.6% while only 1.8% among hepatitis B virus infection (p<0.001).
Table 1: Baseline characteristics of study subjects
HBsAg positive (n=27475) | Anti-HCV positive (n=1950) | P value | ||
---|---|---|---|---|
Male n (%) | 23211(84.7) | 1471(75.4) | NS | |
Female n (%) | 4264(15.3) | 479(24.6) | NS | |
Age group (yrs) (all cases) | ||||
18-30 | 36/14382(0.3) | 6/268(2.2) | <0.001 | |
31-40 | 152/7039(2.2) | 64/450(14.2) | <0.001 | |
41-50 | 168/3635(4.6) | 131/483(27.1) | <0.001 | |
51-60 | 120/1659(7.2) | 143/438(32.6) | <0.001 | |
> 60 | 39/760(5.1) | 97/311(31.2) | <0.001 | |
Previous history of jaundice (Yes) n (%) | 5714(20.8) | 380(19.5) | NS | |
History of blood transfusion (Yes) n (%) | 330(1.2) | 177(9.1) | <0.001 | |
Status of liver disease | ||||
Acute hepatitis n (%) | 2940(10.7) | 21(1.1) | <0.001 | |
Chronic hepatitis n (%) | 20139(73.3) | 1169(59.9) | NS | |
Compensated cirrhosis n (%) | 2638(9.6) | 481(24.7) | <0.001 | |
De-compensated cirrhosis n (%) | 1758(6.4) | 279(14.3) | <0.001 | |
ALT U/L, median (range) | 49(19-4541) | 68(23-3318) | <0.001 | |
Diabetes present n (%) | 515(1.8%) | 441(22.6%) | <0.001 |
International Journal of Life-Sciences Scientific Research (IJLSSR)
Open Access Policy
Authors/Contributors are responsible for originality, contents, correct
references, and ethical issues.
IJLSSR publishes all articles under Creative Commons
Attribution- Non-Commercial 4.0 International License (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/legalcode |
How to cite this article: Azam G, Alam S, Khan AS, Giasuddin RS, Khan M: High Prevalence of Diabetes Mellitus among Adult Patients with Viral Hepatitis C than Hepatitis B. Int. J. Life. Sci. Scienti. Res., 2017; 3(5):1365-1369. DOI:10.21276/ijlssr.2017.3.5.17 Source of Financial Support:Nil, Conflict of interest: Nil |